(19)
(11) EP 4 168 556 A2

(12)

(88) Date of publication A3:
21.04.2022

(43) Date of publication:
26.04.2023 Bulletin 2023/17

(21) Application number: 21748991.3

(22) Date of filing: 23.06.2021
(51) International Patent Classification (IPC): 
C12N 15/67(2006.01)
A61K 48/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/67; A61K 48/0066; C12N 15/88; C12N 2830/50
(86) International application number:
PCT/US2021/038780
(87) International publication number:
WO 2021/262909 (30.12.2021 Gazette 2021/52)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 23.06.2020 US 202063042822 P
23.03.2021 US 202163165094 P
24.03.2021 US 202163165469 P

(71) Applicant: ModernaTX, Inc.
Cambridge, MA 02139 (US)

(72) Inventors:
  • REID, David
    Cambridge, MA 02139 (US)
  • JAIN, Ruchi
    Cambridge, MA 02139 (US)
  • BICKNELL, Alicia
    Cambridge, MA 02139 (US)
  • KOHRER, Caroline
    Cambridge, MA 02139 (US)

(74) Representative: Griffin, Philippa Jane et al
Mathys & Squire The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

   


(54) LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE